Ipsen: Cabometyx approved by the FDA two months ahead of schedule

Ipsen’s recently partnered drug cabozantinib was approved yesterday in the US by the FDA in 2nd line RCC, well ahead of schedule. Top-line OS data are included in the press release (HR=0.66)